Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 59 |
Updated: | 3/16/2019 |
Start Date: | November 20, 2014 |
End Date: | December 21, 2020 |
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
This is a multi-center, randomized, double-blinded, placebo controlled trial in
pre-menopausal women with advanced breast cancer.
The purpose of this study is to assess the efficacy of Ribociclib (LEE011), as measured by
progression free survival (PFS), in premenopausal women with HR positive, HER2 negative
advanced breast cancer
pre-menopausal women with advanced breast cancer.
The purpose of this study is to assess the efficacy of Ribociclib (LEE011), as measured by
progression free survival (PFS), in premenopausal women with HR positive, HER2 negative
advanced breast cancer
Inclusion Criteria:
- Patient has advanced (locoregionally recurrent or metastatic) breast cancer not
amenable to curative therapy
- Patient is premenopausal or perimenopausal at the time of study entry
- Patients who received (neo) adjuvant therapy for breast cancer are eligible
- Patient has a histologically and/or cytologically confirmed diagnosis of
estrogen-receptor positive and/or progesterone receptor positive breast cancer
- Patient has HER2-negative breast cancer
- Patient must have either measurable disease or If no measurable disease is present,
then at least one predominantly lytic bone lesion
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Patient has adequate bone marrow and organ function
Exclusion Criteria:
- Patient who has received a prior CDK4/6 inhibitor
- Patient is postmenopausal
- Patients who currently have inflammatory breast cancer at screening.
- Patients who received any prior hormonal anti-cancer therapy for advanced breast
cancer, except for ≤ 14 days of tamoxifen or NSAI ± goserelin for advanced breast
cancer prior to randomization.
- Patient has a concurrent malignancy or malignancy within 3 years of randomization,
with the exception of adequately treated basal cell skin carcinoma, squamous cell skin
carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
- Patient with CNS metastases.
- Patient has active cardiac disease or a history of cardiac dysfunction
- Patient is currently using other antineoplastic agents
- Patient is pregnant or nursing or physiologically capable of becoming pregnant and not
using highly effective contraception
Other protocol-defined Inclusion/Exclusion may apply.
We found this trial at
43
sites
Santa Barbara, California 93110
Principal Investigator: Julie Taguchi
Phone: 805-898-2117
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Ursa Brown-Glaberman
Phone: 505-925-0371
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
Principal Investigator: Anne F. Schott
Phone: 734-936-8538
Click here to add this to my saved trials
Bakersfield, California 93309
Principal Investigator: Ravindranath Patel
Phone: 661-616-1619
Click here to add this to my saved trials
Baltimore, Maryland 21231
Principal Investigator: Vered Stearns
Phone: 410-502-3696
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Aditya Bardia
Phone: 617-643-2208
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: Rajni Sinha
Phone: 423-778-2982
Click here to add this to my saved trials
Click here to add this to my saved trials
Danbury, Connecticut 06810
Principal Investigator: Michael Cohenuram
Phone: 203-739-6985
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Sarah Conlon
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Yuan Yuan
Phone: +1 626 256 4673 64546
Click here to add this to my saved trials
Durham, North Carolina 27710
Principal Investigator: Kimberly Blackwell
Phone: 919-660-1278
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
Everett, Washington 98201
(425) 297-5500
Principal Investigator: Peter Jiang
Phone: 425-297-5532
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
Click here to add this to my saved trials
Fort Myers, Florida 33901
Principal Investigator: Marilyn Raymond
Phone: 561-472-1596
Click here to add this to my saved trials
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Robyn Ruble Young
Click here to add this to my saved trials
Greenville, South Carolina 29601
Principal Investigator: Stephen Dyar
Phone: 864-603-6211
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Cristina Truica
Phone: 717-531-5777
Click here to add this to my saved trials
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Jennifer Carney
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Debasish Tripathy
Phone: 713-792-2768
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Angel Augusto Rodriguez
Phone: +1 713 441 6011
Click here to add this to my saved trials
Houston, Texas 77090
Principal Investigator: Laurent Gressot
Phone: 832-330-5090
Click here to add this to my saved trials
Click here to add this to my saved trials
Kennewick, Washington 99336
Principal Investigator: Rangaswamy Chintapatla
Phone: 509-783-4637
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Teresa Helsten
Phone: 858-657-7676
Click here to add this to my saved trials
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Sara Alsterlind Hurvitz
Phone: +1 310 582 4069
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Janell Seeger
Phone: 502-629-3673
Click here to add this to my saved trials
Madison, Wisconsin 53792
Principal Investigator: Kari Wisinski
Phone: 608-265-2999
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Raul C. Oyola
Phone: 770-281-5131
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Reshma Mahtani
Phone: 954-698-3673
Click here to add this to my saved trials
Midlothian, Virginia 23114
Principal Investigator: William Irvin
Phone: 804-894-8665
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Denise A. Yardley
Phone: 615-329-7664
Click here to add this to my saved trials
Click here to add this to my saved trials
Ogden, Utah 84403
Principal Investigator: Vincent Hansen
Phone: 801-387-7406
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Suleiman Massarweh
Phone: 650-723-0628
Click here to add this to my saved trials
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
Principal Investigator: Haeseong Park
Phone: 314-362-0263
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Virginia Kaklamani
Phone: 210-450-1789
Click here to add this to my saved trials
San Antonio, Texas 78234
Principal Investigator: Robert Setlik
Phone: 210-916-0706
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Sibel Blau
Phone: 253-383-3366
Click here to add this to my saved trials